curcumin

Overview

Curcumin, a polyphenolic compound derived from the rhizome of Curcuma longa (turmeric), is recognized for its diverse biological activities and potential therapeutic applications. It exhibits anti-inflammatory, antioxidant, and anticancer properties, making it a subject of extensive research in various fields of medicine. The mechanism of action of curcumin involves modulation of multiple signaling pathways, including the nuclear factor kappa B (NF-κB) pathway, transforming growth factor-beta (TGF-β), and the PI3K/Akt signaling pathway, which play critical roles in inflammation, cell proliferation, and apoptosis. Due to its hydrophobic nature and poor bioavailability, curcumin's clinical application has been limited, prompting the development of novel delivery systems to enhance its therapeutic efficacy.

Recent Publications Focus

Below is a summary of the newest research publications targeting curcumin (sorted by publication date).

Recent studies have increasingly focused on curcumin's neuroprotective mechanisms across multiple central nervous system disorders. In Parkinson's disease models, curcumin attenuated cuproptosis and activated autophagy through inhibition of the AKT/mTOR/P70S6K-signaling pathway, preserving dopaminergic neurons and reducing α-synuclein accumulation. Similar neuroprotective strategies were demonstrated in exertional heat stroke and traumatic brain injury, where nanocurcumin and curcumin formulations suppressed inflammatory signaling pathways—notably the TLR4/MyD88/NF-κB axis—while reducing neuronal injury and modulating neuroendocrine dysfunction. Additionally, curcumin mitigated gas explosion-induced traumatic brain injury by modulating cAMP signaling and reducing neuroinflammatory markers including interleukin-1β and TNF-α, highlighting curcumin's multi-target anti-inflammatory role in CNS pathology.

A significant research focus has been addressing curcumin's inherent bioavailability limitations through diverse formulation strategies. Numerous studies developed nanocrystal systems, polymer-based micelles, extracellular vesicles derived from lactic acid bacteria, chitosan conjugates, and protein-based carriers to enhance solubility, cellular uptake, and tissue penetration. These delivery platforms consistently improved drug loading efficiency, sustained release kinetics, and biological efficacy compared to free curcumin. Notably, pH-responsive systems and surface modifications with targeting ligands (biotin, hyaluronic acid) or functional excipients (zinc ions) demonstrated enhanced therapeutic outcomes by optimizing curcumin retention, cellular internalization, and localized action at sites of pathology.

Curcumin's anti-inflammatory and immunomodulatory properties were extensively evaluated in chronic inflammatory and metabolic disorders. In inflammatory bowel disease, curcumin-loaded extracellular vesicles from lactic acid bacteria positively modulated gut microbiota composition while reducing inflammatory cytokines. In comorbid depression and psoriasis, curcumin downregulated matrix metalloproteinase-9 and apoptotic pathways, alleviating both pathological conditions. Curcumin also suppressed atherosclerosis-associated inflammation by inhibiting the P2X7R-mediated pathway and reducing oxidative stress markers. In type 2 diabetes, computational and experimental validation identified curcumin as a multi-target natural therapeutic enhancing insulin-stimulated glucose uptake and modulating key metabolic regulators including GLP1R and PPARG.

In oncology, curcumin was evaluated across multiple cancer types including breast cancer, melanoma, hepatocellular carcinoma, and glioblastoma multiforme, with studies demonstrating synergistic efficacy when combined with conventional chemotherapeutics or delivered via advanced targeting platforms. ROS-responsive polymeric nanoparticles co-delivering curcumin with cinnamaldehyde disrupted tumor redox homeostasis and achieved 86% tumor growth inhibition. Biotin-conjugated and receptor-targeted nanocarrier systems enhanced blood-brain barrier penetration and glioblastoma cell accumulation. Curcumin-based formulations also demonstrated antimicrobial and regenerative properties in oral (periodontitis and acne) and dermatological applications, with photodynamic antimicrobial microneedles achieving 99.4% bacterial inhibition against Propionibacterium acnes when combined with near-infrared irradiation. These findings collectively position curcumin as a versatile therapeutic scaffold when formulated appropriately for targeted tissue delivery.

Background PMIDs

[PMID 41882965]

Method PMIDs

[PMID 41846095]
[PMID 42201771]
[PMID 42244174]
[PMID 42269888]
[PMID 42319075]

Result PMIDs

[PMID 41895974]
[PMID 42319075]

Target PMIDs

[PMID 41519009]
[PMID 41619422]
[PMID 41713562]
[PMID 41725216]
[PMID 41734550]
[PMID 41740377]
[PMID 41806650]
[PMID 41819914]
[PMID 41831974]
[PMID 41832025]
[PMID 41833848]
[PMID 41844085]
[PMID 41844107]
[PMID 41855861]
[PMID 41895946]
[PMID 41895974]
[PMID 41895977]
[PMID 41923660]
[PMID 41934301]
[PMID 41935781]
[PMID 41942223]
[PMID 41943310]
[PMID 41944076]
[PMID 41962485]
[PMID 41973041]
[PMID 41974179]
[PMID 41995291]
[PMID 41996327]
[PMID 41999919]
[PMID 42012656]
[PMID 42025660]
[PMID 42036630]
[PMID 42055359]
[PMID 42056079]
[PMID 42061133]
[PMID 42061627]
[PMID 42084949]
[PMID 42090188]
[PMID 42107576]
[PMID 42108873]
[PMID 42115500]
[PMID 42120914]
[PMID 42142675]
[PMID 42153286]
[PMID 42155926]
[PMID 42170973]
[PMID 42216664]
[PMID 42223732]
[PMID 42231964]
[PMID 42264249]
[PMID 42300103]
[PMID 42319083]
[PMID 42324759]
[PMID 42384231]
[PMID 42396648]
[PMID 42410284]